Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats.

Unis A, Abdelbary A, Hamza M.

Can J Physiol Pharmacol. 2014 Mar;92(3):226-33. doi: 10.1139/cjpp-2013-0168. Epub 2013 Dec 20.

PMID:
24593787
2.

Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.

Li G, Wu XW, Lu WH, Ai R, Chen F, Tang ZZ.

BMC Cardiovasc Disord. 2014 Oct 18;14:145. doi: 10.1186/1471-2261-14-145.

3.

Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.

Yang LX, Heng XH, Guo RW, Si YK, Qi F, Zhou XB.

J Cardiovasc Pharmacol. 2013 Aug;62(2):205-11. doi: 10.1097/FJC.0b013e3182967fc0.

PMID:
23615158
4.

Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats.

Cetinkaya Demir B, Uyar Y, Ozbilgin K, Köse C.

J Obstet Gynaecol Res. 2013 Jan;39(1):229-36. doi: 10.1111/j.1447-0756.2012.01969.x. Epub 2012 Jul 29.

PMID:
22845341
5.

Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.

Sun Y, Liu J, Yang B, Sai X, Li T, Wang D, Zhou R.

APMIS. 2014 Jun;122(6):556-64. doi: 10.1111/apm.12185. Epub 2013 Oct 29.

PMID:
24164644
6.

MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.

Nachtigal P, Pospisilova N, Pospechova K, Jamborova G, Kopecky M, Jaynes R, Briestensky J, Santar I, Smahelova A, Solichova D, Zdansky P, Semecky V.

Life Sci. 2006 Mar 20;78(17):1983-9. Epub 2005 Nov 21.

PMID:
16305803
7.

Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits.

Du B, Xu G, Cao H, Cui W, Lin S, Liu Y, Qin L.

J Cardiovasc Med (Hagerstown). 2013 Feb;14(2):120-6. doi: 10.2459/JCM.0b013e3283541fca.

PMID:
22609871
8.

Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.

Gocmen AY, Ocak GA, Ozbilim G, Delibas N, Gumuslu S.

Can J Physiol Pharmacol. 2013 Sep;91(9):680-5. doi: 10.1139/cjpp-2012-0325. Epub 2013 Apr 8.

PMID:
23984971
9.

Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.

Sezer ED, Sozmen EY, Nart D, Onat T.

Vasc Health Risk Manag. 2011;7:333-43. doi: 10.2147/VHRM.S17781. Epub 2011 Jun 1.

10.

Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.

Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G.

Circulation. 2013 Jun 11;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534. Epub 2013 May 8.

11.

Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.

Worthley SG, Helft G, Corti R, Worthley MI, Chew DP, Fayad ZA, Zaman AG, Fallon JT, Fuster V, Badimon JJ.

Pathophysiol Haemost Thromb. 2007;36(1):9-17. doi: 10.1159/000112634. Epub 2008 Mar 6.

PMID:
18332609
12.

Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.

Moon JH, Kang SB, Park JS, Lee BW, Kang ES, Ahn CW, Lee HC, Cha BS.

Metabolism. 2011 Jul;60(7):930-40. doi: 10.1016/j.metabol.2010.08.013. Epub 2010 Oct 15.

PMID:
20951395
13.

Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.

Berbée JF, Wong MC, Wang Y, van der Hoorn JW, Khedoe PP, van Klinken JB, Mol IM, Hiemstra PS, Tsikas D, Romijn JA, Havekes LM, Princen HM, Rensen PC.

J Nutr Biochem. 2013 Aug;24(8):1423-30. doi: 10.1016/j.jnutbio.2012.11.009. Epub 2013 Jan 18.

PMID:
23337345
14.

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.

Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J.

J Am Coll Cardiol. 1998 Dec;32(7):2057-64.

15.

Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.

Nachtigal P, Jamborova G, Pospisilova N, Pospechova K, Solichova D, Zdansky P, Semecky V.

J Pharm Pharm Sci. 2006;9(2):222-30.

16.

Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.

Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Kihara T, Tanaka N, Nakaya K, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F.

Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):222-8. doi: 10.1097/HJR.0b013e32832948a0.

PMID:
19242355
17.

Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.

Srinivas M, Annapurna A, Reddy YN.

Indian J Exp Biol. 2008 Oct;46(10):698-703.

PMID:
19024167
18.

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.

Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ.

Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2416-21. Epub 2005 Sep 1.

19.
20.

Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model.

Fotis L, Agrogiannis G, Vlachos IS, Pantopoulou A, Margoni A, Kostaki M, Verikokos C, Tzivras D, Mikhailidis DP, Perrea D.

In Vivo. 2012 Mar-Apr;26(2):243-50.

PMID:
22351665

Supplemental Content

Support Center